Jump to Main Content
Diabetes and Risk of Prostate Cancer: A study using the National Health Insurance
- Tseng, Chin-Hsiao
- Diabetes care 2011 v.34 no.3 pp. 616-621
- Asians, comorbidity, diabetes, health insurance, hyperlipidemia, hypoglycemic agents, insulin, kidney diseases, men, myocardial ischemia, patients, prostatic neoplasms, regression analysis, relative risk, risk factors, Taiwan
- OBJECTIVE: The link between diabetes and prostate cancer is rarely studied in Asians. RESEARCH DESIGN AND METHODS: The trend of age-standardized prostate cancer incidence in 1995-2006 in the Taiwanese general population was calculated. A random sample of 1,000,000 subjects covered by the National Health Insurance in 2005 was recruited. A total of 494,630 men for all ages and 204,741 men ≥40 years old and without prostate cancer at the beginning of 2003 were followed to the end of 2005. Cumulative incidence and risk ratio between diabetic and nondiabetic men were calculated. Logistic regression estimated the adjusted odds ratios for risk factors. RESULTS: The trend of prostate cancer incidence increased significantly (P < 0.0001). The cumulative incidence markedly increased with age in either the diabetic or nondiabetic men. The respective risk ratio (95% CI) for all ages and age 40-64, 65-74, and ≥75 years was 5.83 (5.10-6.66), 2.09 (1.60-2.74), 1.35 (1.07-1.71), and 1.39 (1.12-1.71). In logistic regression for all ages or for age ≥40 years, age, diabetes, nephropathy, ischemic heart disease, dyslipidemia, living region, and occupation were significantly associated with increased risk, but medications including insulin and oral antidiabetic agents were not. CONCLUSIONS: Prostate cancer incidence is increasing in Taiwan. A positive link between diabetes and prostate cancer is observed, which is more remarkable in the youngest age of 40-64 years. The association between prostate cancer and comorbidities commonly seen in diabetic patients suggests a more complicated scenario in the link between prostate cancer and diabetes at different disease stages.